Loading market dashboard
Envista Holdings Corp
NVSTHealthcareNYSEUS
Loading disclosure news
News and disclosures filtered by period, publisher, and event group.
Select a headline to open the full news page in the app.
Envista (NVST) reported earnings 30 days ago. What's next for the stock?
Envista trades at 15.1x forward earnings; Q1 2026 profit surged, and a $24 target hinges on sustaining margins and sales gains.
Envista targets margin gains via its Business System while boosting R&D and buybacks, with a $24 6-12 month target vs $22.94.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
On May 20, 2026, Envista Holdings Corp (NVST) shares rose 3.1% to a current price of $23.77. This move comes in the context of a 52-week range of $16.41 to $30.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
With consumer sentiment sitting at 53.3 in March 2026, deep in pessimistic territory, retail investors are hunting for defensive names that can grow even as households tighten budgets.
Envista NYSE: NVST reported a strong start to 2026, with management citing broad-based growth across its major dental businesses, margin expansion and continued investment in new products and commercial capabilities.
Explore Envista's (NVST) international revenue trends and how these numbers impact Wall Street's forecasts and what's ahead for the stock.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
My existing 'buy' rating for Envista is left unchanged following my evaluation of its results and outlook. NVST's 1Q2026 earnings beat consensus by 15%, thanks to a defensive dental market and the company's own cost reduction efforts. The company's high-teens EPS growth guidance for the full year is well-supported by new product launches and synergies relating to its latest M&A.
Envista Holdings Corporation (NVST) Q1 2026 Earnings Call Transcript
The headline numbers for Envista (NVST) give insight into how the company performed in the quarter ended March 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Envista (NVST) came out with quarterly earnings of $0.36 per share, beating the Zacks Consensus Estimate of $0.31 per share. This compares to earnings of $0.24 per share a year ago.
BREA, Calif., May 6, 2026 /PRNewswire/ -- Envista Holdings Corporation (NYSE: NVST) today announced results for the quarter ended April 3, 2026.
Stagezero Life Sciences (OTCMKTS:SZLSF - Get Free Report) and Envista (NYSE: NVST - Get Free Report) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, risk, dividends, earnings and valuation. Valuation and Earnings This table compares Stagezero Life
Cwm LLC boosted its stake in Envista Holdings Corporation (NYSE: NVST) by 55.9% during the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 72,217 shares of the company's stock after buying an additional 25,905 shares during the period. Cwm LLC's holdings
BREA, Calif., April 8, 2026 /PRNewswire/ -- Envista Holdings Corporation (NYSE: NVST) ("Envista") will report financial results for its first quarter 2026 on Wednesday, May 6, 2026.
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Envista Holdings Corporation's NVST strategic priorities position it for robust growth in the upcoming quarters. The company is positioned to benefit from favorable long-term dental industry trends.
Envista NVST shares have climbed 42.5% over the past year, showcasing impressive momentum. The stock has outpaced the industry's 22.5% decline and the S&P 500 composite's 16.6% gain.
Investors with an interest in Medical - Products stocks have likely encountered both Envista (NVST) and Stryker (SYK). But which of these two stocks presents investors with the better value opportunity right now?
Nephros (NASDAQ: NEPH - Get Free Report) and Envista (NYSE: NVST - Get Free Report) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, analyst recommendations, valuation, earnings and risk. Volatility and Risk Nephros has a beta of 1.42, indicating
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
OPRX, NVST and STRT made it to the Zacks Rank #1 (Strong Buy) value stocks list on March 16, 2026.
Envista (NVST) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
EAT, PAHC and NVST made it to the Zacks Rank #1 (Strong Buy) value stocks list on March 12th, 2026.
Envista (NVST) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Clarkston Capital Partners LLC decreased its holdings in Envista Holdings Corporation (NYSE: NVST) by 8.2% in the undefined quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 4,317,255 shares of the company's stock after selling 386,075 shares during the quarter. Envista comprises approximately 1.9% of Clarkston
